Cryder Capital Partners Llp buys $9,836,730 stake in PAREXEL International Corporation (PRXL)

PAREXEL International Corporation (PRXL) : Cryder Capital Partners Llp scooped up 26,533 additional shares in PAREXEL International Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment management firm now holds a total of 148,906 shares of PAREXEL International Corporation which is valued at $9,836,730.PAREXEL International Corporation makes up approximately 7.55% of Cryder Capital Partners Llp’s portfolio.

Other Hedge Funds, Including , Creative Planning boosted its stake in PRXL in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 8,247 shares of PAREXEL International Corporation which is valued at $544,797.New England Research Management boosted its stake in PRXL in the latest quarter, The investment management firm added 3,725 additional shares and now holds a total of 20,911 shares of PAREXEL International Corporation which is valued at $1,315,093. PAREXEL International Corporation makes up approx 1.15% of New England Research Management’s portfolio.

PAREXEL International Corporation closed down -0.58 points or -0.87% at $65.92 with 3,08,663 shares getting traded on Friday. Post opening the session at $66.83, the shares hit an intraday low of $65.56 and an intraday high of $66.935 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, PAREXEL International Corporation reported $0.89 EPS for the quarter, based on the information available during the earnings call on Apr 27, 2016. Analyst had a consensus estimate of $0.89. The company had revenue of $527.10 million for the quarter, compared to analysts expectations of $523.31 million. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.66 EPS.

Many Wall Street Analysts have commented on PAREXEL International Corporation. Credit Suisse Initiated PAREXEL International Corporation on Jun 21, 2016 to “Outperform”, Price Target of the shares are set at $75.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Leave a Reply

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.